Results 41 to 50 of about 32,521 (269)

Phosphoinositides and inositol phosphates as molecular glues

open access: yesFEBS Letters, EarlyView.
Inositol phosphates (IPs) and phosphoinositides (PIPs) regulate diverse eukaryotic processes. Beyond recruiting signaling proteins or acting as structural cofactors, recent studies suggest they mediate protein–protein interactions as natural molecular glues.
Aleshia Seaton‐Terry   +9 more
wiley   +1 more source

A geometric proof of Stallings' Theorem on groups with more than one end

open access: yes, 2004
Stallings showed that a finitely generated group which has more than one end splits as an amalgamated free product or an HNN extension over a finite subgroup.
Niblo, Graham
core   +1 more source

Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis

open access: yesFEBS Letters, EarlyView.
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee   +7 more
wiley   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

open access: yesFEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Identifying Significant Features in Cancer Methylation Data Using Gene Pathway Segmentation

open access: yesCancer Informatics, 2016
In order to provide the most effective therapy for cancer, it is important to be able to diagnose whether a patient's cancer will respond to a proposed treatment.
Zena M. Hira, Duncan F. Gillies
doaj   +1 more source

Group C*-Algebras of Locally Compact Groups Acting on Trees

open access: yesInternational Mathematics Research Notices, 2023
Abstract It was proved by Samei and Wiersma that for every non-compact, closed subgroup $G$ of the automorphism group $\textrm {Aut}(T)$ of a (semi-)homogeneous tree $T$ acting transitively on the boundary $\partial T$ and every $2 \leq q < p \leq \infty $, the quotient map $C^{\ast }_{L^{p+}}(G) \twoheadrightarrow C^{\ast }_{L^{q+
Heinig, Dennis   +2 more
openaire   +3 more sources

Reconstructing enzyme evolution by protein engineering

open access: yesFEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler   +2 more
wiley   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Climate Change and the PSO-HNS

open access: yesPhilippine Journal of Otolaryngology Head and Neck Surgery, 2008
Times have changed and seasons have changed.  I remember with nostalgia the cool December mornings of my childhood, the predictable rains, the smell of clean air in open city spaces, and the sight of stars in the evening sky.
Anne Marie V. Espiritu
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy